Literature DB >> 33430828

Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report.

Ken Takao1, Ayaka Tani1, Tetsuya Suwa2, Yayoi Kuwabara-Ohmura1, Kenta Nonomura1, Yanyan Liu1, Takehiro Kato1, Masami Mizuno1, Takuo Hirota1, Mayumi Enya1, Katsumi Iizuka1, Yukio Horikawa1, Chiemi Saigo3, Yusuke Kito3, Tatsuhiko Miyazaki3, Naoyuki Ohe4, Toru Iwama4, Daisuke Yabe5.   

Abstract

BACKGROUND: Primary central nervous system lymphoma is a rare extra-nodal lymphoma of the central nervous system. Primary central nervous system lymphoma lesions usually appear in the vicinity of the ventricle, and there are few reports of primary central nervous system lymphoma with hypothalamic-pituitary lesions. CASE
PRESENTATION: We treated a 56-year-old male with primary central nervous system lymphoma with the primary lesion in the hypothalamus, which was found by magnetic resonance imaging after sudden onset of endocrinological abnormalities. Initially, he was hospitalized to our department for hyponatremia. Endocrinological examination in conjunction with head magnetic resonance imaging and endoscopic biopsy revealed hypothalamic hypopituitarism and tertiary hypoadrenocorticism caused by a rapidly growing, diffuse large B-cell lymphoma in the hypothalamus. Remission of the tumor was achieved by high-dose methotrexate with whole brain radiotherapy, and some of the hormone responses were normalized.
CONCLUSIONS: While primary central nervous system lymphoma is rare, it is important to note that hypopituitarism can result and that the endocrinological abnormalities can be partially restored by its remission.

Entities:  

Keywords:  Case report; Hypopituitarism; Hypothalamus; PCNSL

Year:  2021        PMID: 33430828      PMCID: PMC7802214          DOI: 10.1186/s12902-020-00675-5

Source DB:  PubMed          Journal:  BMC Endocr Disord        ISSN: 1472-6823            Impact factor:   2.763


  11 in total

Review 1.  Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity.

Authors:  A Giustina; M Gola; M Doga; E A Rosei
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

Review 2.  Primary CNS lymphoma in HIV infection.

Authors:  Dieta Brandsma; Jacoline E C Bromberg
Journal:  Handb Clin Neurol       Date:  2018

3.  Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients.

Authors:  Wilhelm Küker; Thomas Nägele; Agnieska Korfel; Stefan Heckl; Eckhard Thiel; Michael Bamberg; Michael Weller; Ulrich Herrlinger
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 4.  Primary CNS Lymphoma.

Authors:  Christian Grommes; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

Review 5.  The 2016 WHO classification of central nervous system tumors: what neurologists need to know.

Authors:  John C DeWitt; Andreas Mock; David N Louis
Journal:  Curr Opin Neurol       Date:  2017-12       Impact factor: 5.710

6.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Authors:  J L Villano; M Koshy; H Shaikh; T A Dolecek; B J McCarthy
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

7.  Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature.

Authors:  Lei Su; Meilin Ding; Lili Chen; Chen Li; Minxi Lao
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

8.  Brain Tumor Registry of Japan (2005-2008).

Authors: 
Journal:  Neurol Med Chir (Tokyo)       Date:  2017       Impact factor: 1.742

9.  Neuroradiological features of lymphomatosis cerebri: A systematic review of the English literature with a new case report.

Authors:  Long Li; Jia-Hui Rong; Jie Feng
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

Review 10.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.